Ivokana futher EU approval achieved!, page-9

Results due soon?
Janssen Collaboration

Stage 1-completed
The key result was that patientspredicted by PromarkerD to be at high-risk of chronic kidney disease were 13.5times more likely than the low-risk group to develop the disease.
Dr Richard Lipscombe said the results were far-reaching forthe commercial roll-out of the test because they substantiated theeffectiveness of PromarkerD as a prognostic test for diabetic kidney disease ina globally recognised clinical cohort. Proteomics International is now focusedon partnering discussions with suitable organisations to bring PromarkerD topatients in the USA.

Stage 2
Further research is nowbeing undertaken to determine whether patients display an improved prognosisafter treatment, in the form of a lower PromarkerD risk score [ASX: 31 March].This is a complex process, requiring extensive analysis of the large clinicaldata set. Future analysis will also examine the performance of PromarkerD inpredicting cardiovascular disease.

ASX 31 Mar 2020:

The collaboration is dueto continue until November 2020, with both parties to continue to bear theirown costs. Significantly, samples will be tested using the new higher throughputPromarkerD immunoassay, PromarkerD (IA) instead of the mass spectrometryplatform, PromarkerD (MS). Use of PromarkerD (IA) may provide important resultsto support Proteomics International's future FDA regulatory applications. Theadditional clinical samples are currently being shipped to ProteomicsInternational's Perth laboratories and will be analysed over the next 2-3months. Statistical analysis will then be performed on the data, a taskexpected to take 1-2 months.